Franchesca Druggan

Department of Internal Medicine The Ohio State University

关注

立即认领

关注

立即认领

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 10 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

A Study to Assess the Efficacy of Enasidenib and Risk-Adapted Addition of Azacitidine in Newly Diagnosed IDH2-mutant AML

Sheng F. Cai,Ying Huang, Jennie R. Lance,Hsiaoyin Charlene Mao,Andrew J. Dunbar,Samantha N. McNulty,Todd Druley,Yan Li,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William G. Blum,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark Litzow,Tara Lin,Prapti Patel,Matthew C. Foster,Michael Boyiadzis,Robert H. Collins,Jordan Chervin,Abigail Shoben,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Timothy L. Chen,Ashley O. Yocum,Franchesca Druggan,Sonja Marcus,Mona Stefanos,Brian J. Druker,Alice S. Mims,Uma Borate,Amy Burd,John C. Byrd,Ross L. Levine,Eytan M. Stein

Blood advances（2024）

引用0浏览0WOS引用

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESULTS

Alice S. Mims,Ying Huang,Eric D. Eisenmann,Shelley Orwick,Daelynn R. Buelow,Ronan T. Swords,Joshua F. Zeidner,Matthew C. Foster,Tara L. Lin,Maria R. Baer,Yazan F. Madanat,Tibor Kovacsovics,Robert L. Redner,Zeina Al‐Mansour,Mona Stefanos,Molly Martycz,Franchesca Druggan,Timothy Chen,Ashley O. Yocum,Uma Borate,Brian J. Druker,Amy Burd,Ross L. Levine,Sharyn D. Baker,John C. Byrd

HemaSphereno. S3 (2023): e2938119-e2938119

引用0浏览0引用

Entospletinib with Decitabine in Acute Myeloid Leukemia with Mutant TP53 or Complex Karyotype: A Phase 2 Substudy of the Beat AML Master Trial

Vu H. Duong,Amy S. Ruppert,Alice S. Mims,Uma Borate,Eytan M. Stein,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William Blum,Martha L. Arellano,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark R. Litzow,Tara L. Lin,Prapti A. Patel,Matthew C. Foster,Robert L. Redner,Zeina Al-Mansour,Christopher R. Cogle,Ronan T. Swords,Robert H. Collins,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Ashley O. Yocum,Sonja Marcus,Timothy Chen,Franchesca Druggan,Mona Stefanos,Theophilus J. Gana,Abigail B. Shoben,Brian J. Druker,Amy Burd,John C. Byrd,Ross L. Levine,Michael M. Boyiadzis

Cancer（2023）

引用1浏览0WOS引用

A Phase 1b/2 Study of TP-0903 and Decitabine Targeting Mutant TP53 And/or Complex Karyotype in Patients with Untreated Acute Myeloid Leukemia ≥ Age 60 Years: Phase 1b Interim Results

Alice S. Mims,Ying Huang,Eric Eisenmann,Daelynn Buelow,Ronan T. Swords,Matthew Charles Foster,Tara L. Lin,Maria R. Baer,Tibor Kovacsovics,Zeina Al-Mansour,Mona Stefanos,Franchesca Druggan,Timothy Chen,Ashley Yocum,Uma Borate,Brian J. Druker,Amy Burd,Ross L. Levine,Sharyn D. Baker,John C. Byrd

Journal of clinical oncology（2022）

引用1浏览0引用

A Risk-Adapted Study to Assess the Efficacy of Enasidenib and Subsequent Response-Driven Addition of Azacitidine for Newly Diagnosed IDH2-Mutant AML Patients: 3-Year Follow-up

Eytan Stein,Sheng F. Cai,Ying Huang,Andrew Dunbar,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William G. Blum,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark R. Litzow,Tara L. Lin,Prapti A. Patel,Matthew C. Foster,Michael M. Boyiadzis,Robert H. Collins,Jordan Chervin,Abigail B. Shoben,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Timothy Chen,Ashley O. Yocum,Franchesca Druggan,Sonja Marcus,Mona Stefanos,Molly Martycz, Brian J. Druker,Alice S. Mims,Uma Borate,Amy Burd, John C. Byrd,Ross L. Levine

Blood（2022）

引用0浏览0引用

A Phase 1b Dose Escalation and Expansion Study of SNDX-5613, Azacitidine (AZA) and Venetoclax (VEN) in Newly Diagnosed, Patients ≥ 60 Years with Untreated NPM1-Mutated/ FLT3-Wild Type AML or KMT2A-Rearranged Acute Myeloid Leukemia (AML)

Joshua F. Zeidner,Matthew C. Foster, Mary Johnson,Ying Huang,Ronan T. Swords,Eytan Stein,James M. Foran,Maria R. Baer,Wendy Stock,Yazan F. Madanat,Tibor Kovacsovics,Rebecca L. Olin,William G. Blum,Gary J. Schiller,Tara L. Lin,Robert L. Redner,Zeina Al-Mansour,Emily K. Curran,Nyla A. Heerema,Molly Martycz,Leonard Rosenberg,Sonja Marcus,Ashley O. Yocum,Timothy Chen,Mona Stefanos,Franchesca Druggan,Amy Burd,Ross L. Levine,Brian J. Druker,Uma Borate,John C. Byrd,Alice S. Mims

BLOOD（2022）

引用0浏览0引用

Ivosidenib (IVO) in Combination with Azacitidine (AZA) in Newly Diagnosed (ND) Older Patients with IDH1 R132-Mutated Acute Myeloid Leukemia (AML) Induces High Response Rates: A Phase 2 Sub-Study of the Beat AML Master Trial

Prapti Patel,Amy S. Ruppert,Uma Borate,Eytan M. Stein,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William Blum,Martha L. Arellano,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark R. Litzow,Tara L. Lin,Matthew C. Foster,Robert L. Redner,Zeina Al-Mansour,Christopher R. Cogle,Michael M. Boyiadzis,Ronan Swords,Robert H. Collins,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Ashley Owen Yocum,Sonja Marcus,Timothy Chen,Franchesca Druggan,Mona Stefanos,Theophilus J. Gana,Abigail B. Shoben, Brian J. Druker,Amy Burd, John C. Byrd,Ross L. Levine,Alice S. Mims

Blood（2021）

引用0浏览0引用

Entospletinib (ENTO) and Decitabine (DEC) Combination Therapy in Older Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Patients with Mutant TP53 or Complex Karyotype Is Associated with Poor Response and Survival: A Phase 2 Sub-Study of the Beat AML Master Trial

Vu H. Duong,Amy S. Ruppert,Alice S. Mims,Uma Borate,Eytan M. Stein,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William G. Blum,Martha L. Arellano,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark R. Litzow,Tara L. Lin,Prapti A. Patel,Matthew C. Foster,Robert L. Redner,Zeina Al-Mansour,Christopher R. Cogle,Ronan T. Swords,Robert H. Collins,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Ashley O. Yocum,Sonja Marcus,Timothy Chen,Franchesca Druggan,Mona Stefanos,Theophilus J. Gana,Abigail B. Shoben, Brian J. Druker,Amy Burd, John C. Byrd,Ross L. Levine,Michael M. Boyiadzis

BLOOD（2021）

引用0浏览0引用

Gilteritinib (GILT) Monotherapy with Addition of Decitabine (DEC) in Non-Responders in Older Newly Diagnosed (ND) FLT3 Mutated Acute Myeloid Leukemia (AML) Patients Having High and Low Variant Allele Frequency (VAF): A Phase 2/1b Sub-Study of the Beat AML Master Trial

Elie Traer,Ying Huang,Alice S. Mims,Eytan M. Stein,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William Blum,Martha L. Arellano,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark R. Litzow,Tara L. Lin,Prapti Patel,Matthew C. Foster,Robert L. Redner,Zeina Al-Mansour,Christopher R. Cogle,Michael M. Boyiadzis,Ronan Swords,Robert H. Collins,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Ashley O. Yocum,Sonja Marcus,Timothy Chen,Franchesca Druggan,Mona Stefanos,Theophilus J. Gana,Abigail B. Shoben,Brian J. Druker,Amy Burd,John C. Byrd,Ross L. Levine,Uma Borate

Blood（2021）

引用0浏览0引用

Enasidenib (ENA) Monotherapy with Addition of Azacitidine in Non-Responders is Effective in Older Patients with Newly Diagnosed IDH2 Mutated Acute Myeloid Leukemia (AML): A Completed Phase 2/1b Sub-Study of the Beat AML Master Trial

Eytan M. Stein,Ying Huang,Uma Borate,Maria R. Baer,Wendy Stock,Tibor Kovacsovics,William Blum,Gary J. Schiller,Rebecca L. Olin,James M. Foran,Mark Litzow,Tara Lin,Prapti A. Patel,Matthew C. Foster,Michael Boyiadzis,Robert H. Collins,Jo-Anne Vergilio,Nyla A. Heerema,Leonard Rosenberg,Ashley Owen Yocum,Timothy Chen,Franchesca Druggan,Sonja Marcus,Mona Stefanos,Jordan Chervin,Abigail Shoben,Brian J. Druker,Amy Burd,John C. Byrd,Ross L. Levine,Alice S. Mims

Blood（2020）

引用4浏览0引用

作者统计

#Papers: 10

#Citation: 6

H-Index: 1

G-Index: 2

Sociability: 4

Diversity: 1

Activity: 9

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn